Stocks · Healthcare · Biotechnology
PTC Therapeutics, Inc. PTCT
$63.46 -1.04% Close, Oct 2, 2026 · NASDAQ · Market cap $5.30B
High qualityLow risk
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-0.58, down 108.3% year over year.
- Operating margin narrowed to 11.5% from 40.7% a year earlier.
- The diluted share count rose 17.7% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 12%
- EPS growth (TTM, YoY)Bottom 17%
- FCF growth (TTM, YoY)Bottom 11%
- Revenue growth, 3-year CAGRTop 18%
- Revenue growth accelerationTop 13%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 28%
- Gross marginTop 29%
- Operating marginTop 23%
- Accruals (lower is better)Bottom 18%
- Net debt / EBITDA (lower is better)Top 12%
- Interest coverTop 42%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 32%
- Free-cash-flow yieldBottom 46%
- EBITDA / enterprise valueTop 29%
- Sales / enterprise valueBottom 48%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 46%
- 6-month returnBottom 36%
- 1-year return vs S&P 500Bottom 44%
- Distance from 52-week highTop 47%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 14%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 32%
- Upside to consensus price targetTop 48%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 20%
- Maximum drawdown, 3 yearsTop 10%
- Beta vs S&P 500 (lower is better)Top 45%
- Net debt / EBITDA (lower is better)Top 12%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -53.3% | -42.8% | ↑ |
| EPS growth (YoY) | -135.8% | -108.3% | ↑ |
| Gross margin | 97.1% | 82.1% | ↓ |
| Operating margin | 40.7% | 11.5% | ↓ |
| FCF margin | 38.6% | -33.0% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -42.8% | -53.3% | ↑ | Bottom 12% |
| EPS growth (TTM, YoY) | -108.3% | -135.8% | ↑ | Bottom 17% |
| Gross margin | 82.1% | 97.1% | ↓ | Top 29% |
| Operating margin | 11.5% | 40.7% | ↓ | Top 23% |
| Net margin | -3.8% | 35.6% | ↓ | — |
| Free-cash-flow margin | -33.0% | 38.6% | ↓ | — |
| Return on invested capital | 2.6% | — | Top 28% | |
| Revenue growth, 3-year CAGR | 35.3% | — | Top 18% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -0.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 8.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +64.7 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -2.04×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 0.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.93%
- Shareholder yield
- -1.93%
- Share count change, 1 year
- +17.7%
- Share count change, 3-year CAGR
- +7.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- -48.9%
- Average 2-day reaction, last 8
- -1.9%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $106.00
- Target vs current price
- +67.0%
- Analysts with a rating
- 26
- Share rating Buy or Strong Buy
- 65%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | +289.3% | +1.4% | -7.1% | -2.4% | — |
| May 7, 2026 | +93.3% | -3.1% | +10.4% | +6.1% | +2.3% |
| Feb 19, 2026 | -695.2% | +1.4% | -1.7% | -2.8% | +5.5% |
| Nov 4, 2025 | +116.8% | -0.3% | +6.7% | +15.6% | +11.2% |
| Aug 7, 2025 | +22.4% | -1.9% | -6.2% | +12.9% | +32.6% |
| May 6, 2025 | +1029.6% | -11.0% | +13.2% | +24.7% | +28.2% |
| Feb 27, 2025 | +24.1% | -0.8% | +1.9% | +8.5% | -10.7% |
| Nov 7, 2024 | +9.7% | -0.5% | +2.0% | +12.1% | +15.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | $0.92 | $0.24 | +289.3% | $360.5M |
| May 7, 2026 | -$0.03 | -$0.45 | +93.3% | $272.6M |
| Feb 19, 2026 | -$1.67 | -$0.21 | -695.2% | $164.7M |
| Nov 4, 2025 | $0.20 | -$1.19 | +116.8% | $211.0M |
| Aug 7, 2025 | -$0.83 | -$1.07 | +22.4% | $178.9M |
| May 6, 2025 | $10.04 | -$1.08 | +1029.6% | $1.18B |
| Feb 27, 2025 | -$0.85 | -$1.12 | +24.1% | $213.2M |
| Nov 7, 2024 | -$1.39 | -$1.54 | +9.7% | $196.8M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (forward) | 49.9× | — | — | — |
| EV / EBITDA | 28.5× | — | — | Top 29% |
| EV / Sales | 4.90× | — | — | Bottom 48% |
| Free-cash-flow yield | -6.28% | — | — | Bottom 46% |
| Earnings yield | -0.91% | — | — | Top 32% |
P/E over the past five years
Range 5.6× – 9.0× since Mar 31, 2025. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -8.6%
- 200-day average slope (20 days)
- -1.7%
- Distance from 50-day average
- -8.7%
- Distance from 200-day average
- -12.1%
- RSI (14)
- 38.5
- Relative volume
- 0.71×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 38.9%
- Volatility vs own 5-year history
- 18th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.03
- Correlation with S&P 500
- 0.35
- Current drawdown from 1-year high
- -29.1%
- Maximum drawdown, 3 years
- -36.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 7, 2021 | Nov 2, 2023 | -73.8% | 710 days | 503 days (Nov 5, 2025) |
| Jul 9, 2026 | Sep 24, 2026 | -30.4% | 54 days | Not yet recovered |
| Nov 26, 2025 | Mar 6, 2026 | -27.2% | 67 days | 83 days (Jul 7, 2026) |
| Dec 18, 2020 | Jan 4, 2021 | -10.6% | 9 days | 3 days (Jan 7, 2021) |
| Dec 4, 2020 | Dec 7, 2020 | -10.0% | 1 days | 5 days (Dec 14, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $5.30B
- EPS, diluted (TTM)
- -$0.58
- Revenue (TTM)
- $1.01B
- 52-week range
- $61.16 – $90.87
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $538.6M | $698.8M | $937.8M | $806.8M | $1.73B |
| Gross profit | $506.3M | $654.1M | $872.3M | $749.4M | $1.66B |
| Operating income | -$374.4M | -$447.4M | -$439.5M | -$302.6M | $856.5M |
| Net income | -$523.9M | -$559.0M | -$626.6M | -$363.3M | $682.6M |
| EPS (diluted) | -$7.43 | -$7.79 | -$8.37 | -$4.73 | $7.78 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $196.8M | $213.2M | $1.18B | $178.9M | $211.0M | $164.7M | $272.6M | $360.5M |
| Net income | -$106.7M | -$65.9M | $866.6M | -$64.8M | $15.9M | -$135.0M | -$2.8M | $83.5M |
| EPS (diluted) | -$1.39 | -$0.85 | $10.04 | -$0.83 | $0.20 | -$1.67 | -$0.03 | $0.92 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$251.3M | -$356.7M | -$158.4M | -$107.7M | $711.2M |
| Capital expenditure | -$85.3M | -$152.5M | -$120.6M | -$74.2M | -$300.0M |
| Free cash flow | -$336.7M | -$509.1M | -$279.0M | -$181.9M | $411.2M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $23.1M | $50.0M | $0 | $0 | $99.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $2.23B
- Total assets
- $3.25B
- Total liabilities
- $3.42B
- Total debt
- $696.5M
- Net debt
- -$353.4M
- Shareholders’ equity
- -$165.4M
As of Jun 30, 2026 (filed Jul 30, 2026).
Short interest
- Shares sold short
- 9,738,919
- Days to cover
- 11.03
- Change vs previous report
- -0.9%
FINRA short interest, settlement date Sep 15, 2026.